期刊文献+

高效液相色谱法测定非布司他片的含量 被引量:1

下载PDF
导出
摘要 建立反相高效液相色谱法测非布司他片中非布司他的含量。方法:采用奥泰公司C18色谱柱(220 mm×4.6mm,5μm),水-乙腈-乙酸(60:40:0.03)为流动相,检测波长为230nm,流速为1.0ml/min,柱温为30℃。非布司他在2~12mg.mL-1范围内呈良好的线性关系(r=0.99995)。非布司他平均回收率分别为99.5%。结论:本法简便、准确,可用于非布司他片中非布司他的含量测定。
出处 《黑龙江科技信息》 2012年第7期51-51,共1页 Heilongjiang Science and Technology Information
  • 相关文献

参考文献3

  • 1国家药典委员会.中国药典二部[S].北京:化学工业出版社.2010:附录157.
  • 2ERNST ME,FRAVEL MA.Febusxostat:A selective xanthine-oxidase/xanthine-deh?drogenase inhibitor for the management of hy-peruricemia in adults with gout[J].Clin Ther,2009,31(11):2503-2518.
  • 3韩莹,朱翊,傅得兴.非布司他治疗高尿酸血症伴痛风的药理与临床评价[J].中国新药与临床杂志,2010,29(8):635-638. 被引量:30

二级参考文献7

  • 1CHOI HK, MOUNT DB, REGINATO AM. Pathogenesis of gout [J]. Ann Intern Med, 2005, 143(7): 499-516.
  • 2OKAMOTO K, EGER BT, NISHINO T, et al. An extremely potent inhibitor of xanthine oxidoreduetase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition[J]. J Biol Chem, 2003, 278(3) : 1848-1855.
  • 3SCHLESINGER N. Management of acute and chronic gouty arthritis: present state-of-the-art[J]. Drugs, 2004, 64 (21) : 2399- 2416.
  • 4HOSKISON KT, WORTMANN RL. Management of gout in older adults: barriers to optimal control[J]. Drugs Aging, 2007, 24 (1): 21-36.
  • 5Anon. ULORIC.[EB/OL]. [2009-02-13]. http: //www. accessdata. fda. gov/drugsatfdadocs/label/2009/0218561b1. pdf.
  • 6SCHUMACHER HR, BECKER MA, WORTMANN RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28- week, phase Ⅲ, randomized, double-blind, parallel-group trial [J]. Arthritis Rheum, 2008, 59(11 ) : 1540-1548.
  • 7SCHUMACHER HR Jr, BECKER MA, LLOYD E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study[J]. Rheumatology (Oxford), 2009, 48 (2) : 188-194.

共引文献44

同被引文献26

  • 1陈光亮,王琳琳,徐叔云.防治痛风的药物研究进展[J].国外医学(内分泌学分册),2005,25(4):277-279. 被引量:15
  • 2朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8):803-806. 被引量:31
  • 3Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 AmericanCollege of Rheumatology guidelines for management of gout. Part1: systematic on pharmacologic and pharmacologic therapeuticapproaches to hyperuricemia[J]. Arthritis Care Res (Hoboken),2012, 64(10): 1431-1446.
  • 4Okamoto K, Eger BT, Nishino T, et al. An extremely potentinhibitor of xanthine oxidoreductase. Crystal structure of theenzyme-inhibitorcomplex and mechanism of inhibition[J]. J BiolChem, 2003, 278(3): 1848-1855.
  • 5Canivet J, Yamaguchi J, Ban I,et a I. Nickel-catalyzed biarylcoupling of heteroarenes and arylhalides/triflates[J]. OrgLett, 2009,11(8): 1733-1736.
  • 6Komiyama M. Method for producing phenyl substitutedheterocyclic derivative by means of coupling method using apalladium compound[P]. WO 2012 026 565, 2012-03-01.
  • 7Khosravan R, Grabowski B, Wu JT, et al. Pharmacokinetics,pharmacodynamics and safety of fubuxostat, a non-purine selectiveinhibitor of xanthine oxidase, in a dose escalation study in healthysubjects[J]. Clin Pharmacokinet, 2006, 45: 821-841.
  • 8Khosravan R, Grabowski BA, Wu JT, et al. Effect of food or antacidon pharmacokinetics and pharmacodynamics of febuxostat inhealthy subjects[J]. Br J Clin Pharmacol, 2007, 65: 355-363.
  • 9Khosravan R, Grabowski B, Wu JT, et al Effect of food or antacidon pharmacokinetics and pharmacodynamics of febuxostat inhealthy subjects[J], Br J Clin Pharmacol, 2008, 65(3): 355-363.
  • 10Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, issafe and decreases serum urate in healthy volunteers. NucleosidesNucleotides Nucleic Acids, 2004,23(8-9): 1111-1116.

引证文献1

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部